

April 9,2004

Barbara Wedehase, MSW, COC
Executive Director
The National MPS Society
P.O. Box 736
Bangor, ME 044402-0736

Dear Barbara

I would like to extend special thanks to you, other at the MPS Society and the families who have supported TKT in conducting the pivotal 12S trial for MPS II. Together with everyone's support we successfully enrolled the trial in a very short period of time and look forward to completing the study next year in our effort to help all patients suffering from Hunter syndrome.

As you know, we are committed to developing therapies for rare genetic diseases with a major focus on lysosomal storage disorders. Under a much newer initiative, our researchers have been working very hard to understand how we can administer treatments to specially target the central nervous system of certain disorders. We have been evaluating some new approaches to the problem and if the results support it, we hope to conduct a trail to directly administer the enzyme into the central nervous system in MPS II patients in late 2005, at the earliest. If the trial is successful, we hope it will allow us to expand our initiative and potentially move our MPS IIIA program forward. I must however caution you, that while we are hopeful we can find an approach that will allow us to move these important initiatives forward, this is an extremely challenging initiative we are pursuing and there are no guarantees of success.

We look forward to keeping you current on the progress we are making in the MPS area.

Sincerely

Michael J. Astrue
President and Chief Executive Officer